Ironwood Pharmaceuticals to Present at 2016 RBC Capital Markets Global Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Mizuho Securities Reiterates Buy Following Ironwood Pharma's (IRWD) Strong 4Q Results
February 19, 2016 9:30 AM ESTMizuho Securities reiterated a Buy rating and $15.00 price target on Ironwood Pharmaceuticals (NASDAQ: IRWD) following the company's 4Q earnings report. IRWD reported revenues of $53.3M, beating consensus estimates of $44.5M. EPS loss of ($0.09) also came in ahead of consensus' ($0.17). Management also issued... More
Leerink Partners Remains Sidelined After Ironwood Pharma's (IRWD) 4Q
February 19, 2016 7:22 AM ESTLeerink Partners reiterated a Market Perform rating on Ironwood Pharmaceuticals (NASDAQ: IRWD), and cut the price target to $11.00 (from $12.00), following the company's 4Q earnings release. IRWD reported 4Q Linzess sales of ~$130m, coming in slightly below Leerink's estimate of ~$131m. Collaborative revenues of ~$53m were in line with estimates. IRWD plans to progress IW-1701 and IW-1973 into... More
